IV
IVIXF.US Invion Limited
- Market cap
- USD 4.08M
- P/E
- -
- P/B
- 1.82x
- ROE
- -105.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IVIXF.US undervalued?
Graham numberThe Graham number of Invion Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Invion Limited fundamental analysis
No fundamental analysis for Invion Limited yet.
Invion Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial…
Full company profileInvion Limited financial statements
Invion Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 545K | 2.72M | 2.39M | 1.75M | 2.27M | 2.73M | 2.46M | - | 266K |
| Gross Profit | -955K | 545K | 1.16M | 1.31M | 608K | 669K | 804K | 3.69M | -849K | -925K |
| Operating Income | -1.60M | -710K | -1.77M | -707K | -1.18M | -1.60M | -1.10M | -3.78M | -3.48M | -3.92M |
| EBITDA | -3.89M | -2.90M | -1.54M | -520K | -972K | -1.30M | -640K | -3.05M | -2.63M | -2.73M |
| Net Income | -1.69M | -3.60M | -747K | -657K | -1.11M | -1.55M | -1.08M | -5.63M | -5.80M | -3.90M |
| EPS | -0.11 | -0.09 | -0.01 | -0.01 | -0.02 | -0.03 | -0.02 | -0.09 | -0.08 | -0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 4.46M | 7.65M | 4.25M | 3.97M | 4.24M | 13.8M | 12.7M | 15.5M | 6.25M | 5.65M |
| Total Liabilities | 3.29M | 1.80M | 424K | 225K | 639K | 319K | 433K | 1.01M | 815K | 1.97M |
| Shareholders' Equity | 1.17M | 5.84M | 3.83M | 3.74M | 3.60M | 13.5M | 12.3M | 14.4M | 5.43M | 3.68M |
| Cash & Short-term Investments | 704K | 2.14M | 541K | 426K | 778K | 5.85M | 2.72M | 784K | 560K | 410K |
| Total Debt | 2.87M | - | - | - | - | - | - | - | - | 1.07M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -190K | 522K | -1.48M | -105K | 314K | -765K | -1.21M | -1.60M | -1.95M | -1.64M |
| Capital Expenditure | 6.05K | 6.05K | 4.25K | 75.8K | 3.75 | 5.00M | 1.72M | 900K | 4.00 | 2.84K |
| Free Cash Flow | -190K | 522K | -1.48M | -105K | 314K | -5.77M | -2.92M | -2.50M | -1.95M | -1.64M |
| Ratios | ||||||||||
| ROE | -144.7% | -61.6% | -19.5% | -17.6% | -31.0% | -11.4% | -8.8% | -39.0% | -106.8% | -105.9% |
| ROA | -37.8% | -47.1% | -17.6% | -16.6% | -26.3% | -11.2% | -8.5% | -36.4% | -92.8% | -69.0% |
| Net Profit Margin | - | -660.2% | -27.4% | -27.4% | -63.6% | -68.1% | -39.3% | -228.5% | - | -1,464.2% |
| Debt to Equity | 2.46x | - | - | - | - | - | - | - | - | 0.29x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Invion Limited dividends
Invion Limited has not paid dividends in the last 10 fiscal years.
Last stock split: 1:100 on Nov 20, 2024.
Who owns Invion Limited
- Insiders 41.75%
- Institutions 0.00%
- Public & others 58.25%
- Shares outstanding 111M
- Free float 59.3M
Invion Limited company profile
- Company name
- Invion Limited
- Ticker
- IVIXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- June
- Address
- 385 Bourke Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9692 7222
- Website
- inviongroup.com
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Invion Limited management
3- Mr. Thian ChewExecutive Chairman & CEO
- Ms. Melanie Jaye Leydin B.Bus, C.A.CFO, Company Secretary & Non-Executive Director · born 1973
- Dr. Dean NaylorHead of Intellectual Property Development